Drug Treatment of Intermittent Claudication

被引：0
作者：
Douglas Jacoby
Emile R. Mohler
机构：
[1] University of Pennsylvania School of Medicine,Department of Medicine, Cardiovascular Division
[2] University of Pennsylvania School of Medicine,undefined
来源：
Drugs | 2004年 / 64卷
关键词：
Vascular Endothelial Growth Factor; Peripheral Arterial Disease; Ticlopidine; Pentoxifylline; Cilostazol;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
The US FDA has approved two drugs for the management of intermittent claudication: pentoxifylline and cilostazol. The mechanism of action that provides symptom relief with pentoxifylline is poorly understood but is thought to involve red blood cell deformability as well as a reduction in fibrinogen concentration, platelet adhesiveness and whole blood viscosity. The recommended dose of pentoxifylline is 400mg three times daily with meals. Cilostazol is a potent, reversible, phosphodiesterase III inhibitor. The inhibition of phosphodiesterase allows for the increased availability of cyclic adenosine monophosphate (cAMP). cAMP mediates many agonist-induced platelet inhibitory, vasodilatory and vascular antiproliferative responses. Cilostazol, at a dose of 100mg twice daily, is recommended to be taken 30 minutes before or 2 hours after breakfast and dinner.
引用
收藏
页码：1657 / 1670
页数：13
相关论文
共 195 条
[1]  
Hirsch AT(2001)Peripheral arterial disease detection, awareness, and treatment in primary care JAMA 286 1317-24
[2]  
Criqui MH(1985)The prevalence of peripheral arterial disease in a defined population Circulation 71 510-5
[3]  
Treat-Jacobson D(1996)Diagnosis and treatment of chronic arterial insufficiency of the lower extremities: a critical review Circulation 94 3026-49
[4]  
Criqui MH(2000)Management of peripheral arterial disease (PAD): TASC Working Group. TransAtlantic Inter-Society Concensus (TASC) J Vasc Surg 31 S1-S296
[5]  
Fronek A(2002)Potential emerging therapeutic strategies to prevent restenosis in the peripheral vasculature Catheter Cardiovasc Interv 56 421-31
[6]  
Barrett-Connor E(2000)TransAtlantic Inter-Society Consensus (TASC) Eur J Vasc Endovasc Surg 19 S1-250
[7]  
Weitz JI(1993)Redefining the treatment of peripheral artery disease: role of percutaneous revascularization Circulation 88 1534-57
[8]  
Byrne J(1987)Pentoxifylline: a review of its pharmacodynamic and pharmacokinetic properties, and its therapeutic efficacy Drugs 34 50-97
[9]  
Clagett GP(1982)Pentoxifylline efficacy in the treatment of intermittent claudication: multicenter controlled double-blind trial with objective assessment of chronic occlusive arterial disease patients Am Heart J 104 66-72
[10]  
Dormandy JA(1984)Pentoxifylline in the treatment of intermittent claudication of the lower limbs Angiology 35 389-95
12345678910